Trials / Not Yet Recruiting
Not Yet RecruitingNCT06331260
Assessment of AFP and PIVKA-II as Prognostic Indicators in Liver Transplantation for Hepatocellular Carcinoma
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 600 (estimated)
- Sponsor
- Zhejiang University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
As key biomarkers in HCC, AFP and PIVKA-II reflects biological features of tumor and has been widely applied for clinical diagnosis. Previous studies reported preoperative AFP and PIVKA-II are related to HCC recipient long-term survival after liver transplantation. However, there is no prospective study supporting these conclusions. This study aims to prospective collect liver transplantation cases from multiple transplant centers and further evaluate the prognostic role of preoperative AFP and PIVKA-II in liver transplantation for HCC.
Conditions
- Liver Transplantation
- Hepatocellular Carcinoma
- Alpha-Fetoprotein
- Protein Induced by Vitamin K Absence or Antagonist-II
Timeline
- Start date
- 2024-04-01
- Primary completion
- 2028-04-01
- Completion
- 2028-04-01
- First posted
- 2024-03-26
- Last updated
- 2024-03-26
Source: ClinicalTrials.gov record NCT06331260. Inclusion in this directory is not an endorsement.